It was suggested that since Tregs alleviate the tumor-killing functions of CD8+T cells in the tumor microenvironment, the selective reduction of m6A in tumor-infiltrated Tregs may be advantageous in combination with other methods of cancer immunotherapy [67]. The gene discussed is CD8A; the disease is neoplasm.